Abstract
DNA methylation and histone acetylation are two most studied epigenetic markers. Aberrant methylation of gene promoter regions and histone tail lysine residue modification through acetylation and methylation play a key role in malignant disorders. Two DNA methyltransferase inhibitors, azacitidine and decitabine, have been licensed for clinical therapy for patients with myelodysplastic syndrome. New hypomethylating agents, zebularine and isothiocyanates, are in various stages of development for cancer therapy. In this review we summarize recent clinical developments on novel hypomethylating agents and new regimens from clinical trials for epigenetic therapy of cancer.
Keywords: Epigenetic, chromatin, DNA hypomethylation, azacitidine, decitabine, zebularine
Current Cancer Drug Targets
Title: Clinical Advances in Hypomethylating Agents Targeting Epigenetic Pathways
Volume: 10 Issue: 5
Author(s): S. Cang, Q. Lu, Y. Ma and D. Liu
Affiliation:
Keywords: Epigenetic, chromatin, DNA hypomethylation, azacitidine, decitabine, zebularine
Abstract: DNA methylation and histone acetylation are two most studied epigenetic markers. Aberrant methylation of gene promoter regions and histone tail lysine residue modification through acetylation and methylation play a key role in malignant disorders. Two DNA methyltransferase inhibitors, azacitidine and decitabine, have been licensed for clinical therapy for patients with myelodysplastic syndrome. New hypomethylating agents, zebularine and isothiocyanates, are in various stages of development for cancer therapy. In this review we summarize recent clinical developments on novel hypomethylating agents and new regimens from clinical trials for epigenetic therapy of cancer.
Export Options
About this article
Cite this article as:
Cang S., Lu Q., Ma Y. and Liu D., Clinical Advances in Hypomethylating Agents Targeting Epigenetic Pathways, Current Cancer Drug Targets 2010; 10 (5) . https://dx.doi.org/10.2174/156800910791517217
DOI https://dx.doi.org/10.2174/156800910791517217 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Preparation and Characterization of MKT-077 Nanoparticles for Treatment of Alzheimer’s Disease and Other Tauopathies
Pharmaceutical Nanotechnology Exploration of the Medicinal Peptide Space
Protein & Peptide Letters Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies
Current Pharmaceutical Design Effectiveness of Two Novel Anionic and Cationic Platinum Complexes in the Treatment of Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Herb-Induced Nephrotoxicity
Current Medicinal Chemistry A Computer - Aided Drug Designing for Pharmacological Inhibition of Mutant ALK for the Treatment of Non-small Cell Lung Cancer
Current Topics in Medicinal Chemistry Chronic Inflammation and Cancer: The Role of Endothelial Dysfunction and Vascular Inflammation
Current Pharmaceutical Design Melatonin Prevents Neddylation Dysfunction in Aβ42-Exposed SH-SY5Y Neuroblastoma Cells by Regulating the Amyloid Precursor Protein- Binding Protein 1 Pathway
Current Alzheimer Research Melatonin and Synthetic Melatoninergic Agonists in Psychiatric and Age-associated Disorders: Successful and Unsuccessful Approaches
Current Pharmaceutical Design Dual-Targeted Molecular Probes for Cancer Imaging
Current Pharmaceutical Biotechnology Novel MicroRNA Binding Site SNPs and the Risk of Clear Cell Renal Cell Carcinoma (ccRCC): A Case-Control Study
Current Cancer Drug Targets Polymer Particulates in Drug Delivery
Current Pharmaceutical Design Absorption, Disposition and Pharmacokinetics of Nanoemulsions
Current Drug Metabolism 99mTc-HYNIC-D4 Peptide: A New Small Radiolabeled Peptide for Non Small Cell Lung Tumor Targeting
Anti-Cancer Agents in Medicinal Chemistry Genetics of Cancer Susceptibility
Current Genomics Matrix Systems for siRNA Delivery
Current Topics in Medicinal Chemistry Therapeutically Targeting MicroRNAs in Liver Cancer
Current Pharmaceutical Design Recent Advances in Receptor-Targeted Fluorescent Probes for In Vivo Cancer Imaging
Current Medicinal Chemistry Near-infrared Light Activatable Multimodal Gold Nanostructures Platform: An Emerging Paradigm for Cancer Therapy
Current Cancer Drug Targets The Traces of Sound: Taking the Road to Skin
Current Rheumatology Reviews